JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
31/07/26 - 12:50
Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
20/05/26 - 11:16
Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
08/05/26 - 17:54
Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
20/03/26 - 17:44
Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
16/12/21 - 22:47
DiaSorin 2022-2025 Strategic Plan (552.15 KB)
11/11/21 - 16:56
DiaSorin business momentum and the Luminex acquisition drive Revenues and Profitability up in the first 9 months of 2021 (862.48 KB)
30/07/21 - 12:57
DiaSorin: Revenues and Profitability continue upward momentum in the First Half of 2021, with Guidance raised following the acquisition of Luminex (774.36 KB)
14/05/21 - 16:10
DiaSorin: significant growth in Revenues and Profitability in the first quarter 2021 (756.07 KB)
28/04/21 - 17:46
DiaSorin successfully prices its offer of € 500 million Senior Unsecured Equity-Linked Bonds due 2028 (529.64 KB)
28/04/21 - 7:54
DiaSorin announces its intention to offer € 500 million senior unsecured equity-linked bonds due 2028 (563.02 KB)
11/03/21 - 16:37
Dividend coupon date correction (414.99 KB)
11/03/21 - 15:31